Key result
A systolic blood pressure goal of <140 mm Hg reduces cardiorenal risk, whereas evidence from prospective trials does not currently support a more aggressive goal of <130 mm Hg.
Why the study?
Does intensive blood pressure lowering to <130/80 mm Hg reduce cardiovascular and renal risk compared to <140/90 mm Hg in patients with diabetes or CKD?
Does intensive blood pressure lowering to <130/80 mm Hg reduce cardiovascular and renal risk compared to <140/90 mm Hg in patients with diabetes or CKD?
This review challenges the guideline-recommended blood pressure goal of <130/80 mm Hg for patients with diabetes or CKD, arguing that prospective trial evidence only robustly supports a goal of <140 mm Hg.
Answers are grounded in this paper and cite their sources.
Challenges <130/80 mm Hg targets in diabetes or CKD; leaves open whether prospective trials will support more intensive goals.
Most guidelines in the Western world uniformly recommend two blood pressure (BP) goals, <140/90 mm Hg for the general population and <130/80 mm Hg for those with diabetes or chronic kidney disease (CKD).1,2 These recommendations for a lower BP goal in these specific groups stem from retrospective data analyses that suggest a slower decline in CKD and greater cardiovascular disease (CVD) risk reduction when BP is <130/80 mm Hg. The question to be addressed: are these more aggressive BP goals defensible based on appropriately powered prospective outcome trials? Meta-analyses of all clinical trials, to date, demonstrate that reducing BP reduces risk for stroke and coronary heart disease. However, none have achieved a mean BP goal of <130/80 mm Hg.3 This lack of lower BP goal achievement is even true in CVD outcome trials of diabetes. In trials such as the United Kingdom Prospective Diabetes Study (UKPDS)4 and the Hypertension Optimal Treatment Trial (HOT),5 the systolic BP was more than 10 mm Hg higher than this lower goal. Nevertheless, a benefit occurred on CVD reduction. One prospective study that achieved this lower BP goal in patients with diabetes and no overt nephropathy was the Appropriate Blood Pressure Control in Diabetes (ABCD) trial.6 This trial demonstrated reduced CV risk, but there was no difference between the groups with a mean systolic pressure of 138 mm Hg vs the intensive group at 132 mm Hg. A summary of large CVD outcome trials during the past decade with the relative CVD risk reduction and achieved mean systolic BP are presented in the Figure. It is clear that none of the trials achieved a systolic BP below 130 mm Hg. The definitive answer regarding whether lower levels of systolic BP further reduce CVD risk will come from the results of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial within the year. If negative, the BP goal of <130/80 mm Hg will be clearly indefensible. (A) Association of cardiovascular risk reduction and achieved systolic blood pressure. A summary of large prospective randomized trials. (B) Association of reduced risk of nephropathy progression and achieved systolic blood pressure. A summary of large prospective randomized trials. While there have been more than a dozen appropriately powered, prospective outcome trials that examined the role of various antihypertensive agents on CKD progression, only two trials examined whether a lower BP level slowed nephropathy progression.7 The Modification of Diet in Renal Disease (MDRD) trial was the first randomized trial to examine whether 15-mm Hg lower mean arterial pressure would result in a slower decline in CKD and reduce the risk for renal replacement therapy.8 This trial largely recruited patients without diabetes with advanced nephropathy, mean baseline glomerular filtration rate (GFR) of 39 mL/min, and >500 mg/d of proteinuria. It failed to show a benefit of the lower BP goal on slowing progression. However, after a 12-year follow-up, those with >1 g/d of proteinuria who were allocated to the low BP group, ie, mean BP of 92 mm Hg, manifested a significant decrease in proteinuria and rate of CKD progression.9 Note that the mean systolic BP in the low target group was 126.2±13.6 mm Hg during this follow-up period. Also noteworthy was that the benefit on CKD progression was seen after 1 year at the end of the trial. The second trial to examine prospectively the effects of different BP levels on nephropathy progression was the African American Study of Kidney Disease (AASK).10 It examined African American patients with a GFR between 20 and 65 mL/min/1.73 m2 and albuminuria. It failed to show a benefit of a lower BP level, ie, 128/77 mm Hg, on CKD progression. It did show that in the subset of patients (5%) with 1 g/d of proteinuria had a trend toward a slower decline in kidney function. After an additional 5-year follow-up, yielding a 10-year total follow-up after randomization, no benefit of more aggressive BP reduction was noted on CKD progression.11 These data provide support that a BP goal <130/80 mm Hg will yield a greater benefit in slowing CKD in a subgroup of patients with advanced proteinuric nephropathy, but not for the CKD group as a whole. The data supporting a systolic BP of <140 mm Hg is overwhelming. The Figure summarizes the associated achieved BP reductions in the context of CKD progression. These appropriately powered trials with an end point of CKD progression defined as doubling of creatinine, end-stage renal disease, or death, all strongly support reduction of BP to levels at or below a systolic reading of <140 mm Hg. This is regardless of the diagnosis of diabetes. In summary, the goal of BP-lowering therapy in patients with CKD is to reduce the rate of CKD progression and the risk of CVD.12,13 This cardiorenal risk reduction can be accomplished by reducing and ensuring systolic BP remains <140 mm Hg. The need for further reduction to <130 mm Hg is questionable at this time based on prospective randomized trials. The results of the ACCORD trial may strengthen or eliminate this current lower BP recommendation for those with diabetes.
No takes yet. Share an insight, caveat, or question.
Kalaitzidis et al. (2009) conducted a review in Hypertension, Chronic Kidney Disease, Diabetes. Blood pressure goal <130/80 mm Hg vs. Blood pressure goal <140/90 mm Hg was evaluated on Cardiovascular disease risk reduction and CKD progression. A systolic blood pressure goal of <140 mm Hg reduces cardiorenal risk, whereas evidence from prospective trials does not currently support a more aggressive goal of <130 mm Hg.
Synapse has enriched 10 related papers. Consider them for comparative context: